第14回FACO学術集会レポート

 Report on the 14th International Conference of FACO in Seoul

2026年9月2日～4日にソウル＆Onlineで開催された19th Annual Meeting of the Korean Society of Medical Oncologyに併催し開催された第14回FACO学術集会。

9月4日に「Advancing esophageal cancer care in Asia: From surgery to future precision strategies」と「Advancing cholangiocarcinoma care in Asia: From current standards to future therapeutic strategies」の２テーマで、２つのFACOセッションが開催されました。

日本からの登壇者は、河野浩二先生と池田公史先生です。

The 14th International Conference of FACO was held alongside the 19th Annual Meeting of the Korean Society of Medical Oncology, taking place in Seoul and online from 2 to 4 September 2026.

On 4 September, two FACO sessions were held under the following themes:

• Advancing esophageal cancer care in Asia: From surgery to future precision strategies

Sep. 4 (Fri), 12:10-13:30 Venue Room C

Chair(s)

Dong-Wan Kim (FACO Chairman, KSMO President, Seoul National University Hospital, Korea)

Jin Li (FACO Co-Chair, Shanghai GoBroad Cancer Hospital, China Pharmaceutical University, China)

Session Details

1. Current trends in esophageal cancer surgery in Japan and Asian countries

Koji Kono (FACO CEO, Fukushima Medical University, Japan)

2. Neoadjuvant and perioperative treatment for esophageal cancer: Integrating immunotherapy into clinical practice in Asia

Feng Wang (Sun Yat-Sen University Cancer Center, China)

3. Toward precision care in esophageal cancer: Asian perspectives on biomarkers and future directions

Sook Ryun Park (Asan Medical Center, Korea)

• Advancing cholangiocarcinoma care in Asia: From current standards to future therapeutic strategies

Sep. 4 (Fri), 14:40-16:00 Venue Room C

Chair(s)

Hei-Cheul Jeung (Severance Hospital, Korea)

Masafumi Ikeda (National Cancer Center Hospital East, Japan)

Session Details

1. First-line treatment for advanced cholangiocarcinoma: Evolving standards in Asia

Masafumi Ikeda (National Cancer Center Hospital East, Japan)

2. Biomarker-driven therapy for cholangiocarcinoma: Emerging precision oncology in Asia

Haitao Zhao (Peking Union Medical College Hospital, China)

3. Future directions in cholangiocarcinoma: Building Asian collaboration for next-generation therapies

Jung Yong Hong (Samsung Medical Center, Korea)

第57回日本膵臓学会大会

 The 57th Annual Meeting of the Japan Pancreas Society

７月24日（金）～25日（土）に福岡で開催された第57回日本膵臓学会大会、

上野誠先生が座長をつとめる２日目の ワークショップ「UR-M膵がんに対する集学的治療」において、岡野尚弘先生が『 初診時転移性膵癌におけるConversion Surgeryの治療成績：PC-CURE-1サブ解析』を発表しました。

At the 57th Annual Meeting of the Japan Pancreas Society in Fukuoka (24–25 July 2026), Dr. Naohiro Okano delivered a presentation. The talk took place on Day 2 during the workshop "Multidisciplinary Treatment for UR-M Pancreatic Cancer," chaired by Dr. Makoto Ueno. Dr. Okano presented on the topic: "Outcomes of Conversion Surgery for Treatment-Naïve Metastatic Pancreatic Cancer: A Subanalysis of PC-CURE-1."

膵癌試験について第126回日本外科学会定期学術集会で発表

[126th JSS] Presenting Our Pancreatic Cancer Study

札幌で開催された第126回日本外科学会定期学術集会会期中の4月25日、PC-CURE-1試験の共同研究者・高橋秀典先生が、「Impact of Induction FOLFIRINOX versus Gemcitabine with Nab-Paclitaxel on Early Recurrence and Post-Recurrence Survival after Conversion Surgery for Unresectable Pancreatic Cancer.」を発表。

On April 25, during the 126th Annual Congress of the Japan Surgical Society held in Sapporo, Prof. Hidenori Takahashi, a co-investigator of the PC-CURE-1 study, presented a talk titled:

“Impact of Induction FOLFIRINOX versus Gemcitabine with Nab-Paclitaxel on Early Recurrence and Post-Recurrence Survival after Conversion Surgery for Unresectable Pancreatic Cancer.”